Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) presented initial findings from its Phase 1 HEAT clinical trial evaluating 177Lu-RAD202, a radiopharmaceutical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE